DOI QR코드

DOI QR Code

Anticancer Activity of Atractylodes lancea (Thunb.) DC in a Hamster Model and Application of PET-CT for Early Detection and Monitoring Progression of Cholangiocarcinoma

  • Plengsuriyakarn, Tullayakorn ;
  • Matsuda, Naoki ;
  • Karbwang, Juntra ;
  • Viyanant, Vithoon ;
  • Hirayama, Kenji ;
  • Na-Bangchang, Kesara
  • Published : 2015.10.06

Abstract

Opisthorchis viverrini (OV)-induced cholangiocarcinoma (CCA) is an important cancer in the Great Mekong region, particularly in Thailand. Limitations of treatment options and the lack of an effective diagnostic tool for early detection of CCA are major concerns for the control of this type of cancer. The aim of the study was to investigate anti-CCA activity of the ethanolic extract of Atractylodes lancea (Thunb.) DC., and the applicability of positron emission tomography-computed tomography (PET-CT) as a tool for detection and monitoring the progression of CCA in Opisthorchis viverrini (OV)/dimethylnitrosamine (DMN)-induced CCA hamsters. Male Syrian hamsters were used for toxicity tests and anti-CCA activity evaluation. Development of CCA was induced by initial feeding of 50 metacercariae of OV, followed by drinking water containing 12.5 ppm of DMN in hamsters. The ethanolic extract of A. lancea (Thunb.) DC. was administered orally for 30 days. PET-CT was performed every 4 weeks after initiation of CCA using 18F-fluorodeoxyglucose ($^{18}F-FDG$). Results from the present study suggest that the ethanolic extract of A. lancea (Thunb.) DC. rhizome exhibited promising anti-CCA activity and safety profile in the OV/DMN-induced hamster model. To successfully apply PET-CT as a tool for early detection of tumor development and progression, modification of radiolabeling approach is required to improve its specificity for CCA cells.

Keywords

Cholangiocarcinoma;anticancer;PET-CT;Atractylodes lancea (Thunb.) DC

References

  1. Breitenstein S, Apestegui C, Clavien PA (2008). Positron emission tomography (PET) for cholangiocarcinoma. HPB (Oxford), 10, 120-1. https://doi.org/10.1080/13651820801992583
  2. Chang AJ, Sohn R, Lu ZH, Arbeit JM, Lapi SE (2013). Detection of rapalog-mediated therapeutic response in renal cancer xenografts using 64Cu-bevacizumab immunoPET. PLoS One, 8, 58949. https://doi.org/10.1371/journal.pone.0058949
  3. Chayamarit K (1995). Thai Medicinal Plants, 5th edn. Department of Forestry, Bangkok.
  4. Chen YM, Chou GX, Wang ZT (2007). Determination of betaeudesmol in rhizome of Atractylodes lancea by RP-HPLC. Zhongguo Zhong Yao Za Zhi, 32, 2265-7
  5. Chen Y, Wu Y, Wang H, Gao K (2012). A new 9-noratractylodin from Atractylodes lancea and the antibacterial activity of the atractylodin derivatives. Fitoterapia, 83, 199-203. https://doi.org/10.1016/j.fitote.2011.10.015
  6. Cherry S, Gambhir S (2007). Use of positron emission tomography in animal research. ILAR J, 42, 219-32.
  7. Cohade C, Osman M, Leal J, Wahl RL (2003). Direct comparison of $^{18}F$-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 44, 1797-803.
  8. Khan SA, Toledano MB, Taylor-Robinson SD (2008). Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford), 10, 77-82. https://doi.org/10.1080/13651820801992641
  9. Kubo M, Nogami M, Nishimura M, Moriura T, Arichi S (1983). Origins, processing, and qualities of crude drugs (1). Preventive effects of a Chinese crude drug, Zhu, on experimental stomach ulcer and its pharmacological evaluation. Yakugaku Zasshi, 103, 442-8.
  10. Lardinois D, Weder W, Hany TF, et al (2003). Staging of nonsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med, 348, 2500-7. https://doi.org/10.1056/NEJMoa022136
  11. Laverman P, Blokx WA, Te Morsche RH, et al (2007). [$(^{18})F$] FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. Hepatol Res, 37, 127-32. https://doi.org/10.1111/j.1872-034X.2007.00016.x
  12. Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K (2010). Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement Altern Med, 10, 55. https://doi.org/10.1186/1472-6882-10-55
  13. Mosconi S, Beretta GD, Labianca R, et al (2009). Cholangiocarcinoma. Crit Rev Oncol Hematol, 69, 259-70. https://doi.org/10.1016/j.critrevonc.2008.09.008
  14. Nakai Y, Kido T, Hashimoto K, et al (2003). Effect of the rhizomes of Atractylodes lancea and its constituents on the delay of gastric emptying. J Ethnopharmacol, 84, 51-5. https://doi.org/10.1016/S0378-8741(02)00260-X
  15. Nogami M, Moriura T, Kubo M, Tani T (1986). Studies on the origin, processing and quality of crude drugs. II. Pharmacological evaluation of the Chinese crude drug "zhu" in experimental stomach ulcer. (2). Inhibitory effect of extract of Atractylodes lancea on gastric secretion. Chem Pharm Bull (Tokyo), 34, 3854-60. https://doi.org/10.1248/cpb.34.3854
  16. Nojima H, Kimura I, Kimura M (1992). Blocking action of succinylcholine with beta-eudesmol on acetylcholineactivated channel activity at endplates of single muscle cells of adult mice. Brain Res, 575, 337-40. https://doi.org/10.1016/0006-8993(92)90101-E
  17. O'Dell MR, Huang JL, Whitney-Miller CL, et al (2012). Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res, 72, 1557-67. https://doi.org/10.1158/0008-5472.CAN-11-3596
  18. OECD (2004). Acute Oral Toxicity, Guideline 420, the OECD guideline for testing of chemical.
  19. OECD (2008). Repeated dose 28-day oral toxicity study in rodents, guideline 407, the OECD guideline for testing of chemical.
  20. Ouyang Z, Yang L, Su SL, Feng X, Wang M (2007). Fingerprint of volatile oil of Atractylodes lancea by GC-MS. Acta Pharmaceutica Sinica, 42, 968-72.
  21. Plengsuriyakarn T, Viyanant V, Eursitthichai V, et al (2012). Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med, 12, 23. https://doi.org/10.1186/1472-6882-12-23
  22. Plengsuriyakarn T, Viyanant V, Eursitthichai V, Na-Bangchang K (2012). In vitro investigations on the potential roles of Thai medicinal plants in treatment of cholangiocarcinoma. Int Res Pharm Pharmacol, 2, 52-63.
  23. Resch M, Steigel A, Chen Z, Bauer R (1998). 5-Lipoxygenase and cyclooxygenase-1 inhibitory active compounds from Atractylodes lancea. J Nat Prod, 61, 347-50. https://doi.org/10.1021/np970430b
  24. Resch M, Heilmann J, Steigel A, Bauer R (2001). Further phenols and polyacetylenes from the rhizomes of Atractylodes lancea and their anti-inflammatory activity. Planta Med, 67, 437-42. https://doi.org/10.1055/s-2001-15817
  25. Rizvi S, Gores GJ (2013). Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterol, 145, 1215-29. https://doi.org/10.1053/j.gastro.2013.10.013
  26. Sacks A, Peller PJ, Surasi DS, et al (2011). Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR, 197, 260-65. https://doi.org/10.2214/AJR.11.6995
  27. Singh MK, Facciuto ME (2012). Current management of cholangiocarcinoma. Mt Sinai J Med, 79, 232-45. https://doi.org/10.1002/msj.21298
  28. Sithithaworn P, Andrews RH, Nguyen VD, et al (2012). The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitol Int, 61, 10-6. https://doi.org/10.1016/j.parint.2011.08.014
  29. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K (2004). Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health, 9, 588-94. https://doi.org/10.1111/j.1365-3156.2004.01234.x
  30. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL (2005). Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology, 237, 1038-45. https://doi.org/10.1148/radiol.2373040555
  31. Thamavit W, Kongkanuntn R, Tiwawech D, Moore MA (1987). Level of opisthorchis infestation and carcinogen dosedependence of cholangiocarcinoma induction in Syrian golden hamsters. Virchows Arch B Cell Pathol Incl Mol Pathol, 54, 52-8. https://doi.org/10.1007/BF02899196
  32. Tsuneki H, Ma EL, Kobayashi S, et al (2005). Antiangiogenic activity of beta-eudesmol in vitro and in vivo. Eur J Pharmacol, 512, 105-15. https://doi.org/10.1016/j.ejphar.2005.02.035
  33. Wang Y, Dai CC, Chen Y (2009). Antimicrobial activity of volatile oil from Atractylodes lancea against three species of endophytic fungi and seven species of exogenous fungi. Ying Yong Sheng Tai Xue Bao, 20, 2778-84.
  34. Xiao PG, Li DP, Yang SL (2002). Modern Chinese materia medica. chemical industry press, Beijing.
  35. Yeh CN, Lin KJ, Hsiao IT, et al (2008). Animal PET for thioacetamide-induced rat cholangiocarcinoma: a novel and reliable platform. Mol Imaging Biol, 10, 209-16. https://doi.org/10.1007/s11307-008-0141-8
  36. Zhang H, Han T, Sun LN, et al (2008). Regulative effects of essential oil from Atractylodes lancea on delayed gastric emptying in stress-induced rats. Phytomed, 15, 602-11. https://doi.org/10.1016/j.phymed.2008.02.005
  37. Zhang J, Han C, Wu T (2012). MicroRNA-26a promotes cholangiocarcinoma growth by activating $\beta$-catenin. Gastroenterol, 143, 246-56. https://doi.org/10.1053/j.gastro.2012.03.045

Cited by

  1. (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics vol.2017, pp.1741-4288, 2017, https://doi.org/10.1155/2017/5929234

Acknowledgement

Supported by : National Research University Project of Thailand (NRU)